Fig. 7: Characterization of HN878’s trehalose catalytic shift activity.
A treS mRNA expression levels in HN878 and lineage 4 strains (e.g., H37Rv, Erdman, and CDC1551) were measured before and after treatment with RIF. The closed black circles indicate fold changes relative to untreated controls. Data points represent mean values ± s.e.m. of biological triplicates. B Growth kinetics of HN878 and lineage 4 strains on m7H9 with trehalose as the sole carbon source. The effect of ValA on HN878 growth is also illustrated. Values represent mean values ± s.e.m. of triplicates. C RIF treatment induced changes in the levels of trehalose, glucose 6P, and pentose 5P in HN878 and lineage 4 strains, relative to the untreated controls (No RIF). FC, fold change. Values are mean values ± s.e.m. of biological triplicates. D The effects of ValA (left panel) or CRISPRi-mediated treS inactivation (right panel) on the rates of RIF-resistance acquisition per generation in HN878 and lineage 4 clinical strains, measured via the classical fluctuation assay. Values are mean values ± s.e.m. of biological triplicates. p values were determined by Student’s unpaired t-test with Welch’s correction, ns, not significant. In a box plot (right panel), data depict median (center bar), 25th and 75th percentile (lower and upper box bounds), and minimum and maximum values (lower and upper whiskers). E Impact of ValA on the IC50 values of RIF against the indicated Mtb clinical strains: HN878 (~62 ng/mL), ERD (~31 ng/mL), CDC1551 (~22 ng/mL) and HN878 treated with ValA (~22 ng/mL). Source data are provided as a Source Data File.
